Clinical trialPhase 2Completed
Nab-Paclitaxel + Cisplatin + Gemcitabine in Untreated Metastatic Pancreatic Adenocarcinoma
A Phase II Trial of Nab-Paclitaxel Plus Cisplatin Plus Gemcitabine in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
- Outcome
- Results posted; single-arm, no comparison
- Phase
- Phase 2
- Status
- Completed
- Study type
- Interventional
- Start
- 15 July 2019
- Ended
- 23 January 2023
- Enrollment
- 42 participants
- Sites
- 4
- Primary outcomes
- 12- Month Overall Survival (OS)
- Sponsor type
- Academic / other
- Results posted
- 23 April 2026
- Last update
- 23 April 2026
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Results
- Primary endpoint
- Results posted; single-arm, no comparisonAs posted on ClinicalTrials.gov ↗, registry record of 23 April 2026
- OS
- 12- Month Overall Survival (OS)NabCG: 16 of 42Values: ParticipantsTime frame: 12 monthsNo analysis posted for this outcome (outcome 1)
- Participants
- NabCG: 42 started, 42 completed
- Serious adverse events
- NabCG: 28 of 42Participants with at least one serious adverse event, of those at risk, as posted
7 secondary outcomes
- Toxicity Adverse Events (Grade ≥ 3)
- Blood and lymphatic system disorders - Anemia : T…: NabCG 20/42 [Participants] (first of 19 rows)
- Complete Response Rate (CR)
- NabCG 0 (0 to 9.5), n=37 [percentage of participants, 97.5% Confidence Interval]
- DCR · Disease Control Rate (CR, PR, SD) at 9 Weeks
- Complete Response (CR): NabCG 0/34 [Participants] (first of 3 rows)
- Change in CA 19-9 or CA 125
- CA 19-9: NabCG -1047 (-9675 to -44.0), n=35 [median U/mL, Inter-Quartile Range] (first of 2 rows)
- Rate of Tumor Marker Normalization
- NabCG 10/36 [Participants]
- Quality of Life: MD Anderson Symptom Inventory (MDASI-GI)
- Core symptom severity: NabCG -0.5 (-1.3 to -0.1), n=28 [median score on a scale, Inter-Quartile Range] (first of 3 rows)
- Pain Control: Brief Pain Inventory (BPI)
- Pain severity: NabCG -0.8 (-2.5 to 0.0), n=42 [median change in pain score, Inter-Quartile Range] (first of 2 rows)
Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This is a phase II open-label study evaluating the efficacy and safety of nab-paclitaxel cisplatin, and gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma.
Detailed description public domain (ClinicalTrials.gov)
This is a phase II open-label study evaluating the efficacy and safety of nab-paclitaxel cisplatin, and gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma. An individual cycle of therapy will be defined as Days 1 and 8 every 21 days. Multiple cycles may be administered until the patient is withdrawn from therapy. Overall response rates as well as individual categories of response complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD) will be determined using RECIST 1.1. Time-to-event endpoints, including progression-free survival (PFS) and overall survival (OS) will be assessed using the Kaplan-Meier method. Evaluation of stable disease at 9 weeks will also be assessed. Toxicity (adverse events) will be recorded using the NCI CTCAE, version 5.0.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
12- Month Overall Survival (OS) [12 months]. Count Of Participants, Participants. NabCG (n=42): 16.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Toxicity Adverse Events (Grade ≥ 3) [12-months]. Count Of Participants, Participants. Blood and lymphatic system disorders - Anemia : Total: NabCG (n=42): 20. Gastrointestinal disorders - Colitis : Total: NabCG (n=42): 2. Gastrointestinal disorders - Diarrhea : Total: NabCG (n=42): 5. Gastrointestinal disorders - Enterocolitis : Total: NabCG (n=42): 1. Gastrointestinal disorders - Mucositis oral : Total: NabCG (n=42): 1. General disorders and administration site conditions - Fatigue : Total: NabCG (n=42): 3. General disorders and administration site conditions - Gait disturbance : Total: NabCG (n=42): 1. Infections and infestations - skin infestations : Total: NabCG (n=42): 1. Investigations - Lymphocyte count decreased : Total: NabCG (n=42): 1. Investigations - Neutrophil count decreased : Total: NabCG (n=42): 11. Investigations - Platelet count decreased : Total: NabCG (n=42): 27. Investigations - White blood cell decreased : Total: NabCG (n=42): 7. Metabolism and nutrition disorders - Anorexia : Total: NabCG (n=42): 1. Metabolism and nutrition disorders - Hypocalcemia : Total: NabCG (n=42): 1. Metabolism and nutrition disorders - Hypokalemia : Total: NabCG (n=42): 4. Metabolism and nutrition disorders - Hyponatremia : Total: NabCG (n=42): 1. Musculoskeletal and connective tissue disorders - Generalized muscle weakness : Total: NabCG (n=42): 1. Nervous system disorders - Peripheral sensory neuropathy : Total: NabCG (n=42): 3. Renal and urinary disorders - Acute kidney injury : Total: NabCG (n=42): 1.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Complete Response Rate (CR) [63 days]. Number, percentage of participants (97.5% Confidence Interval). NabCG (n=37): 0 (0 to 9.5).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Disease Control Rate (CR, PR, SD) at 9 Weeks [63 days]. Count Of Participants, Participants. Complete Response (CR): NabCG (n=34): 0. Partial Response (PR): NabCG (n=34): 12. Stable Disease (SD): NabCG (n=34): 19.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Change in CA 19-9 or CA 125 [End of Study (36 months)]. Median, U/mL (Inter-Quartile Range). CA 19-9: NabCG (n=42): -1047 (-9675 to -44.0). CA 125: NabCG (n=42): -67 (-127 to -51). Analysis, NabCG: p=0.001; Wilcoxon signed-rank test; other. Analysis, NabCG: p=0.438; Wilcoxon signed-rank test; other.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Rate of Tumor Marker Normalization [12 months]. Count Of Participants, Participants. NabCG (n=36): 10.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Quality of Life: MD Anderson Symptom Inventory (MDASI-GI) [Baseline to Midpoint (C4/D1)]. Median, score on a scale (Inter-Quartile Range). Core symptom severity: NabCG (n=28): -0.5 (-1.3 to -0.1). Overall symptom distress (interference): NabCG (n=28): -0.3 (-0.9 to 0.0). Gastrointestinal module: NabCG (n=28): 0.0 (-0.6 to 0.2). Analysis, NabCG: p=0.006; Wilcoxon signed-rank test; other. Analysis, NabCG: p=0.048; Wilcoxon signed-rank test; other. Analysis, NabCG: p=0.437; Wilcoxon signed-rank test; other.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Pain Control: Brief Pain Inventory (BPI) [Baseline to Midpoint (C4/D1)]. Median, change in pain score (Inter-Quartile Range). Pain severity: NabCG (n=42): -0.8 (-2.5 to 0.0). Pain Interference: NabCG (n=42): -0.4 (-1.1 to 0.0). Analysis, NabCG: p=0.013; Wilcoxon signed-rank test; other. Analysis, NabCG: p=0.032; Wilcoxon signed-rank test; other.